Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma
Yanan Zheng(Zhejiang Chinese Medical University), Chen Li(Shanghai Jiao Tong University), Rongrong Zheng, Zhenggang Zhu(Wuhan Center for Disease Control and Prevention), Min Yan(Zhengzhou University), Chao Yan(Shanghai Jiao Tong University), Zhenqiang Wang(Shanghai Jiao Tong University), Zhiguo Hou(Jiangsu Hengrui Medicine (China))
Cited by 17
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway
|Oncotarget|2017|400
miR-126 functions as a tumour suppressor in human gastric cancer
|Cancer Letters|2010|298
CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3β/β-catenin pathway
|Journal of Experimental & Clinical Cancer Research|2019|231
Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell
|World Journal of Gastroenterology|2018|212